Full-Time

Specialist IS Automation Engineer

Posted on 11/23/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
IT & Security (1)
Requirements
  • Doctorate degree / Master's degree / Bachelor's degree and 8 to 13 years of experience in Computer Science, IT or related field
  • Hands-on experience administering DocuSign in a regulated enterprise environment
  • Experience implementing secure and validated workflow automations involving approvals, routing, conditional logic and integrations while maintaining appropriate SDLC documentation
  • Proficiency with DocuSign APIs, connectors, and common integration patterns (e.g., REST APIs, native platform connectors) to enable integration with CRM, ERP and other cloud platforms
  • Hands-on experience or strong familiarity with automation and orchestration platforms such as Power Automate and UiPath, with the ability to design and implement workflow-based solutions
  • Proficient in DocuSign Admin and Templates, including custom fields, conditional logic, and workflow configuration
Responsibilities
  • Own the administration, governance, and technical configuration of the DocuSign platform including account setup, permissions, templates, and integrations
  • Partner with business and engagement teams to understand use case requirements and translate them into efficient, compliant DocuSign workflows
  • Design, build, and deliver DocuSign integrations with enterprise systems (e.g., ServiceNow, Salesforce, Veeva, etc.) via APIs, connectors, and middleware tools
  • Ensure compliance with regulatory requirements such as EU eIDAS, FDA 21 CFR Part 11, and GxP standards in all DocuSign implementations
  • Act as liaison between technical IS teams and business/QA teams to ensure proper validation, testing, and documentation of e-signature workflows
  • Develop and maintain solution architecture documents, technical SOPs, and configuration baselines for the DocuSign platform
  • Establish and drive standard methodologies for electronic signature workflow design, data handling, security, and auditing
  • Monitor platform usage and performance; proactively see opportunities for automation improvements, troubleshooting, and scalability
  • Stay current with DocuSign product updates and assess applicability to internal roadmap and business opportunities
  • Conduct training, onboarding, and support activities for business users and IS staff on DocuSign capabilities and governance
  • Lead and participate in vendor management activities including licensing, support issues, and roadmap planning
  • Debugging envelope and recipient errors, tracking envelope history via the DocuSign console or API
Desired Qualifications
  • Experience implementing front-end integrations solutions (e.g., iFrames, redirect flows, responsive signing, mobile)
  • Understanding of e-signature regulations including eIDAS (EU), FDA 21 CFR Part 11, and global GxP compliance requirements
  • Understanding of enterprise IT change management, documentation, and validation practices (e.g., SDLC, CSV, IQ/OQ)
  • Familiarity with compliance frameworks like HIPAA, GDPR, and FedRAMP.
  • Excellent critical-thinking and problem-solving skills
  • Strong communication and collaboration skills
  • Demonstrated awareness of how to function in a team setting
  • Demonstrated awareness of presentation skills
  • Ability to manage multiple projects and priorities with minimal supervision
  • Analytical mindset: Understanding business requirements and mapping them to DocuSign capabilities.
  • Documentation skills: Writing integration guides, API usage documents, and support runbooks.
  • Communication: Collaborating with business users, legal teams, and IT.
  • Problem-solving: Troubleshooting errors in document flows, signature logic, and data mapping.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • MariTide's four-to-six-dose regimen could improve adherence and support obesity launch uptake.
  • IMDYLLTRA's Phase 3 survival benefit strengthens Amgen's oncology pipeline and commercial credibility.
  • Repatha growth, strong free cash flow, and AI efficiency support margin expansion.[1]

What critics are saying

  • Prolia's declining sales expose Amgen to erosion in its mature osteoporosis franchise.
  • MariTide still faces Phase 3, manufacturing, and tolerability execution risk before launch.
  • Tavneos regulatory scrutiny and tarlatamab safety concerns can limit near-term revenue conversion.

What makes Amgen unique

  • Amgen spans oncology, inflammation, rare disease, and general medicine across 100 countries.[1][3]
  • It combines biologics manufacturing with AI-driven discovery and development workflows.[1][5]
  • MariTide and IMDYLLTRA give Amgen distinct obesity and small-cell lung cancer growth options.[1]

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Amgen who can refer or advise you

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE